WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global uncertainties.

WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences ...

WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences ...

Wuxi Biologics (Cayman), Inc. is an investment holding company, which engages in the discovery, development and manufacture of biologics services. Its ...

Amid a global expansion spree at WuXi Biologics, the company's immunization-focused subsidiary has christened its inaugural CDMO site in China.

The U.S. House of Representatives took another step to curb Chinese companies’ U.S. operations by passing a draft of the Biosecure Act.

A Chinese city says it has destroyed a billion pieces of personal data collected during the pandemic, as local governments gradually dismantle their coronavirus surveillance and tracking systems ...

With the specter of the BIOSECURE Act clouding its future, China’s WuXi App Tech sustained its fourth straight quarter with a revenue decline.

CDMO WuXi AppTec issued a surprisingly upbeat 2024 forecast on Monday despite concerns stemming from a national security-related crackdown in the U.S.

WuXi XDC, which spun off from WuXi Bio And WuXi STA in November, has forged a partnership with the South Korean biotech IntoCell. As part of the pact, IntoCell will provide drug-linker ...